The regression equation is:
y = 1.15 – 0.251 x₁ + 0.078 x₂ + 0.306 x₁x₂
<span>
<span>
<span>
Where,
x₁ = -0.2508
x₂ = 0.0777
x₁x₂ = 0.3058
Inserting the values,
<span>
<span>
</span></span>y = 1.15 – {0.251 × (-0.2508)} + {0.078 ×(0.0777)} + {0.306 × (0.3058)}
</span></span></span>
y = 1.15 - (- 0.0629508) + 0.0060606 + 0.935748
y = 1.15 + 0.0629508 + 0.0060606 + 0.935748
y = 1.3125862
Answer:
x₁ and x₂ are main effects (a type of tuna and type of packing liquid) that contribute significant information for the prediction of <span>y.</span>
Answer:
true I know the answer because my teacher told me
Explanation:
During the process of photosynthesis, cells use carbon dioxide and energy from the Sun to make sugar molecules and oxygen. ... Then, via respiration processes, cells use oxygen and glucose to synthesize energy-rich carrier molecules, such as ATP, and carbon dioxide is produced as a waste product.
Answer:
Several 2',3'-dideoxy-3'-thiapyrimidine nucleosides were studied for their ability to inhibit hepatitis B virus (HBV) DNA replication in a HBV-transfected cell line (2.2.15). 2',3'-Dideoxy-3'-thiacytidine (SddC) and 5-fluoro-2',3'-dideoxy-3'-thiacytidine(5-FSddC) were found to be the most potent anti-HBV compounds of those examined. Both compounds resulted in nearly complete cessation of viral DNA replication at 0.5 microM, as monitored by the absence of both intracellular episomal and secreted viral DNAs. The HBV-specific RNAs were not reduced at concentrations that completely blocked HBV DNA replication, suggesting that the inhibitory target is HBV DNA synthesis. The antiviral action of SddC and 5-FSddC was reversible. The concentration of SddC and 5-FSddC required to inhibit 50% of 4-day cell growth in culture was 37 microM and more than 200 microM, respectively. Unlike 2',3'-dideoxycytidine, these two compounds do not affect mitochondrial DNA synthesis in cells at concentrations lower than that required to inhibit cell growth. In view of the potent and selective antiviral activity, both SddC and 5-FSddC should be further evaluated for the treatment of human HBV infection.
Explanation:
